Pillar Biosciences, Inc., the leader in Decision Medicine™, announced its participation in the 2025 Association for Molecular Pathology (AMP) Annual Meeting in Boston, MA. The company and scientific collaborators will collectively present eight studies and host three corporate workshops, showcasing their latest advancements in rapid Next-Generation Sequencing (NGS) and oncology diagnostics. https://mma.prnewswire.com/media/2053175/Pillar_biosciences_Logo.jpg “The data being […]

— Genesis House transforms Korean folklore into light and color with CHROMA: Tales Between Hues Genesis today unveiled CHROMA: Tales Between Hues, an immersive installation at the brand's flagship Genesis House in New York created in collaboration with Tony, Grammy and Critics Choice-nominated actress and singer Ashley Park. Recognized for her acclaimed work on stage

Awards Spotlight MobileX's AI-Driven Approach, CEO Leadership and Expanding Momentum in the Independent Dealer Channel MobileX, the most customizable wireless service designed to save consumers money, today announced it has earned three major industry honors from Fast Company, Mobile Breakthrough and Wave7 Research. The recognitions underscore MobileX's innovation, leadership and accelerating growth in the wireless

Pomerantz LLP is investigating claims on behalf of investors of Organogenesis Holdings Inc.(“Organogenesis” or the “Company”)(NASDAQ: ORGO).Such investors are advised to contact Danielle Peyton atnewaction@pomlaw.comor 646-581-9980, ext. 7980. https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg The investigation concerns whether Organogenesis and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information

Pomerantz LLP is investigating claims on behalf of investors of Trinseo PLC (“Trinseo” or the “Company”) (NYSE: TSE).Such investors are advised to contact Danielle Peyton at newaction@pomlaw.comor 646-581-9980, ext.7980. https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg The investigation concerns whether Trinseo and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for

Pomerantz LLP is investigating claims on behalf of investors of CarMax, Inc. (“CarMax” or the “Company”) (NYSE: KMX).Such investors are advised to contact Danielle Peyton at newaction@pomlaw.comor 646-581-9980, ext.7980. https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg The investigation concerns whether CarMax and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for

Pomerantz LLP is investigating claims on behalf of investors of Stitch Fix, Inc. (“Stitch Fix” or the “Company”) (NASDAQ: SFIX).Such investors are advised to contact Danielle Peyton at newaction@pomlaw.comor 646-581-9980, ext.7980. https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg The investigation concerns whether Stitch Fix and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

Pomerantz LLP announces that a class action lawsuit has been filed against Marex Group Plc (“Marex” or the “Company”)(NASDAQ: MRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.comor 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares

Pomerantz LLP announces that a class action lawsuit has been filed against aTyr Pharma, Inc. (“aTyr” or the “Company”)(NASDAQ: ATYR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.comor 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares

Pomerantz LLP announces that a class action lawsuit has been filed against RCI Hospitality Holdings, Inc. (“RCI” or the “Company”)(NASDAQ: RICK). Such investors are advised to contact Danielle Peyton atnewaction@pomlaw.comor 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares